Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Depreciation and Depletion (2018 - 2025)

Historic Depreciation and Depletion for Autolus Therapeutics (AUTL) over the last 5 years, with Q3 2025 value amounting to $2.1 million.

  • Autolus Therapeutics' Depreciation and Depletion rose 1052.63% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.2 million, marking a year-over-year increase of 1081.08%. This contributed to the annual value of $7.6 million for FY2024, which is 1515.15% up from last year.
  • Per Autolus Therapeutics' latest filing, its Depreciation and Depletion stood at $2.1 million for Q3 2025, which was up 1052.63% from $2.1 million recorded in Q2 2025.
  • In the past 5 years, Autolus Therapeutics' Depreciation and Depletion registered a high of $2.1 million during Q2 2025, and its lowest value of $1.4 million during Q3 2023.
  • For the 4-year period, Autolus Therapeutics' Depreciation and Depletion averaged around $1.8 million, with its median value being $1.9 million (2023).
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first plummeted by 2222.22% in 2023, then soared by 3571.43% in 2024.
  • Autolus Therapeutics' Depreciation and Depletion (Quarter) stood at $1.6 million in 2022, then rose by 12.5% to $1.8 million in 2023, then increased by 11.11% to $2.0 million in 2024, then increased by 5.0% to $2.1 million in 2025.
  • Its Depreciation and Depletion stands at $2.1 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.0 million for Q1 2025.